Inozyme Pharma, Inc. financial data

Symbol
INZY on Nasdaq
Industry
Pharmaceutical Preparations
Location
321 Summer Street, Suite 400, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Inozyme Pharma, LLC (to 1/5/2017)
Latest financial report
Q1 2024 - May 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.39 K % +25.4%
Debt-to-equity 39.9 % +121%
Return On Equity -58.7 % -9.88%
Return On Assets -42 % +7.24%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61.9 M shares +41.5%
Common Stock, Shares, Outstanding 61.8 M shares +41.2%
Entity Public Float 128 M USD -47.9%
Common Stock, Value, Issued 6 K USD +50%
Weighted Average Number of Shares Outstanding, Basic 61.8 M shares +41.3%
Weighted Average Number of Shares Outstanding, Diluted 61.8 M shares +41.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 62.1 M USD +29.7%
General and Administrative Expense 19.5 M USD -12.5%
Operating Income (Loss) -81.6 M USD -16.3%
Nonoperating Income (Expense) 4.51 M USD +71.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -77.1 M USD -14.1%
Earnings Per Share, Basic -1.35 USD/shares +8.16%
Earnings Per Share, Diluted -1.35 USD/shares +8.16%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 20.6 M USD -57.9%
Cash, Cash Equivalents, and Short-term Investments 166 M USD +27%
Assets, Current 174 M USD +29.9%
Property, Plant and Equipment, Net 1.32 M USD -33.6%
Operating Lease, Right-of-Use Asset 992 K USD -34%
Other Assets, Noncurrent 354 K USD 0%
Assets 177 M USD +24.8%
Accounts Payable, Current 2.17 M USD +19.3%
Employee-related Liabilities, Current 3.84 M USD +18.9%
Accrued Liabilities, Current 9.31 M USD -6.26%
Liabilities, Current 12.4 M USD -1.39%
Operating Lease, Liability, Noncurrent 669 K USD -58.3%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 58.1 M USD +51.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -105 K USD -192%
Retained Earnings (Accumulated Deficit) -309 M USD -33.2%
Stockholders' Equity Attributable to Parent 119 M USD +15%
Liabilities and Equity 177 M USD +24.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24.5 M USD -38%
Net Cash Provided by (Used in) Financing Activities 159 K USD -99.2%
Net Cash Provided by (Used in) Investing Activities 10.4 M USD -24.5%
Common Stock, Shares Authorized 200 M shares 0%
Common Stock, Shares, Issued 61.8 M shares +41.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9.62 M USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.35 M USD +1281%
Deferred Tax Assets, Valuation Allowance 88.9 M USD +42.3%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 89.3 M USD +41.6%
Operating Lease, Liability 300 K USD 0%
Depreciation 833 K USD +12%
Payments to Acquire Property, Plant, and Equipment 32 K USD -81.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -77.2 M USD -14.4%
Lessee, Operating Lease, Liability, to be Paid 1.71 M USD -36.9%
Property, Plant and Equipment, Gross 3.88 M USD +3.44%
Operating Lease, Liability, Current 934 K USD +11.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 944 K USD -7.09%
Lessee, Operating Lease, Liability, to be Paid, Year One 944 K USD -7.09%
Lessee, Operating Lease, Liability, to be Paid, Year Three 944 K USD -7.09%
Deferred Tax Assets, Operating Loss Carryforwards 43 M USD +19%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5 M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD -100%
Operating Lease, Payments 900 K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 410 K USD -32.7%
Share-based Payment Arrangement, Expense 6.6 M USD -17.9%
Interest Expense 1.33 M USD +304%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%